Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacogenetic Data Integration Into Labeling To Be Discussed By Subcommittee

This article was originally published in The Pink Sheet Daily

Executive Summary

Clinical Pharmacology Subcommittee will meet Nov. 14-15 on several topics including pharmacogenetic data integration and the biomarker-surrogate endpoint project of FDA's "Critical Path" initiative.

You may also be interested in...



Camptosar Reduced Starting Dose Recommended In Patients With Genetic Marker

Patients with the deficiency of a metabolizing enzyme have an increased risk of neutropenia, revised labeling for Pfizer’s oncologic says. Patients with the deficiency should start at a lower dose, though the appropriate starting dose is not known, FDA says.

Pfizer's Camptosar To Serve As Example Of Pharmacogenetic Toxicity Risk At Meeting

Irinotecan will be used as an example of pharmacogenetic toxicity risk at Clinical Pharmacology Subcommittee meeting Nov. 3-4. Pfizer is discussing label changes with FDA regarding Camptosar use in patients with certain genotypes. Subcommittee will also address the transition of biomarkers to surrogate endpoints.

Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter

The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.

Topics

UsernamePublicRestriction

Register

PS061129

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel